

EF Hutton,
division of Benchmark Investments, LLC
590 Madison Avenue, 39th Floor
New York, NY 10022

February 7, 2022

VIA EDGAR

U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Ms. Jordan Nimitz / Ms. Celeste Murphy

Re: TC BioPharm (Holdings) plc

Registration Statement on Form F-1, File No. 333-260492
Registration Statement on Form F-6, File No. 333-262149
Registration Statement on Form 8-A, File No. 001-41231

WITHDRAWAL OF REQUEST FOR ACCELERATION OF EFFECTIVENESS

Requested Date: February 7, 2022
Requested Time: 4:00 pm, Eastern Time

Ladies and Gentlemen:

We hereby withdraw our Request for Acceleration of Effectiveness submitted February 4, 2022.

Very truly yours,

EF Hutton,
division of Benchmark Investments, LLC

By: /s/ Sam Fleischman
Name: Sam Fleischman
Title: Supervisory Principal
